EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokoll

A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol

Luba Yammine, Heather Leidy, Kevin C Maki, Michael F Weaver, Elizabeth A Bodalski, Joy M Schmitz

Contemporary Clinical Trials · 2025-08 · 155 · 107989

DOI: 10.1016/j.cct.2025.107989 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2025-08. Verfasst von Luba Yammine und 5 weiteren Autor:innen. Beteiligte Einrichtung: Louis A. Faillace, M.D., Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, United …. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Smoking Cessation, Weight Gain, Obesity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Smoking and obesity are the two leading causes of preventable morbidity and mortality in the U.S. While smoking cessation has tremendous health benefits, most smokers gain weight post-cessation, which may partially attenuate these benefits. Semaglutide 2.4 mg once-weekly, a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight management in adults with overweight/obesity, leads to clinically meaningful reductions in body weight and may thus have utility for preventing weight gain in the context of smoking cessation. METHODS: This parallel group, two-arm, double-blind clinical trial will randomize 177 treatment-seeking smokers with a body mass index of ≥30 kg/m2 or ≥ 27 kg/m2 with at least one weight-related comorbidity to semaglutide 2.4 mg once-weekly or placebo (2:1) for 28 weeks, including 16 weeks of semaglutide dose escalation, followed by 12 weeks at target, 2.4 mg, dose. Both groups will receive 10 weeks of nicotine patches (dose based on baseline number of cigarettes smoked daily) and brief individual smoking cessation counseling. The primary outcome is percent body weight change at the end of treatment. Secondary outcomes are changes in total body weight and fat mass (kg) and waist circumference. Exploratory outcomes are changes in daily energy intake and food choices, food cravings and appetite/satiety, and smoking abstinence rates. CONCLUSION: We anticipate that semaglutide 2.4 mg once-weekly will provide a clinically meaningful effect on weight management in the context of smoking cessation. If our hypotheses are confirmed, this GLP-1RA could move forward as a pharmacotherapeutic for helping smokers achieve abstinence without weight gain. Universal trial number (UTN): U1111-1270-1737. CLINICAL TRIAL REGISTRATION: NCT06173778.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesSmoking CessationWeight GainObesityOverweightHumansDouble-Blind MethodAdultMaleFemaleMiddle AgedRandomized Controlled Trials as TopicGlucagon-Like Peptide-1 Receptor AgonistsDrug Administration ScheduleBody Mass IndexGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP-1 agonistsGlucagon-like peptide 1ObesityRandomized controlled trialSemaglutideSmokingWeight

Substanzen

Glucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Louis A. Faillace, M.D., Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, United States of America. Electronic address: Luba.Yammine@uth.tmc.edu.
  • Department of Nutritional Sciences, College of Natural Sciences, University of Texas at Austin, Austin, TX, United States of America; Department of Pediatrics, Dell Medical School, University of Texas at Austin, Austin,…
  • Midwest Biomedical Research, Addison, IL, United States of America; Indiana University, School of Public Health, Department of Applied Health Science, Bloomington, IN, United States of America.
  • Louis A. Faillace, M.D., Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, United States of America.

Förderung

  • Novo Nordisk

Zitieren

APA

Yammine, L., Leidy, H., Maki, K. C., Weaver, M. F., Bodalski, E. A., & Schmitz, J. M. (2025). A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol. Contemporary Clinical Trials, 155, 107989. https://doi.org/10.1016/j.cct.2025.107989

Vancouver

Yammine L, Leidy H, Maki KC, Weaver MF, Bodalski EA, Schmitz JM. A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol. Contemporary Clinical Trials. 2025;155:107989. doi:10.1016/j.cct.2025.107989

BibTeX
@article{Yammine2025,
  author = {Yammine, Luba and Leidy, Heather and Maki, Kevin C and Weaver, Michael F and Bodalski, Elizabeth A and Schmitz, Joy M},
  title = {A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  volume = {155},
  pages = {107989},
  doi = {10.1016/j.cct.2025.107989}
}
Kostenlos starten →